{
  "docId": "019de072-afcf-751b-be79-65bbe03fb0c7",
  "docSlug": "a4681640730b4446aa1f6ee077b8a572",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 23,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/3",
  "deckHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7",
  "deckJsonHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json",
  "deckAnchorHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "callout",
      "text": "CORE SCIENCE",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38fd9c7e-654b-4d4b-8572-9d1a242d884e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.02,
        "y": 0.74
      },
      "kind": "callout",
      "text": "RESOURCES",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a185329-ba15-4e2b-ba38-5b28ce67f5b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.4,
        "y": 0.47
      },
      "kind": "callout",
      "text": "FOCUS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a20fe408-4163-49e0-8875-68d60e277e28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.4,
        "y": 0.54
      },
      "kind": "list",
      "text": "Next Generation novel antibody therapeutics\nKey programs: CTX-009, CTX-471 and CTX-8371\nLet the science guide the therapeutic format: monoclonal vs. multispecific",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c3a2c39-f4ad-46e5-95ec-ea8b7f8ee861",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.02,
        "y": 0.32
      },
      "kind": "list",
      "text": "StitchMabs™ platform designed to identify synergistic bispecific antibodies\nCommon Light Chain technology enables multi-specificity and manufacturability\nOur understanding of Cancer Biology informs the design of our proprietary drug candidates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98415b85-65b8-40a2-a3ee-e7a7091f531d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.02,
        "y": 0.8
      },
      "kind": "list",
      "text": "~25 FTEs, based in Boston, MA\nCapable of rapidly advancing candidates from idea to clinical proof-of-concept\nFunded by leading life-science investors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c39c2852-e82d-41fb-9ef8-5dde2c05f7bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "We are a clinical stage biotech company developing antibody therapeutics for cancer & autoimmune diseases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6032c772-b1cb-40e4-b8b4-0fd19f3fe740",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Company Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aeecf998-f2b4-4939-9048-f7b8d860a995",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "6b226ab5-3adf-4ed5-a637-5a8d5e3e58d3",
      "evidence": "list/bullet: We are a clinical stage biotech company",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 3,
      "beatId": "706587f7-3254-4856-9a3c-57a4f888e4b3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The executive summary presents the company's focus on cancer and autoimmune diseases",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667",
      "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company",
      "position": 0,
      "objective": "Highlight the potential consequences of not investing in Compass Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}